TACPAD agenda

TACPAD Agenda 4.8.20.docx

Conference, Meeting, Workshop, and Poster Session Registration Generic Clearance (OD)

TACPAD agenda

OMB: 0925-0740

Document [docx]
Download: docx | pdf

AGENDA

Translational Advances in Cancer Prevention Agent Development

Sponsored by the Division of Cancer Prevention, National Cancer Institute

and the Office of Disease Prevention

National Institutes of Health

Bethesda, MD 20892

DATE: August 27-29, 2020



Day 1 Morning Session (8:00 to 12:00)

7:00-8:00 AM Registration (Please allow sufficient time to go through security)

8:00-8:30 AM Welcome Remarks

Deborah Winn, Ph.D., Acting Director, Division of Cancer Prevention, NCI

Mark Miller, Ph.D. Program Director, Division of Cancer Prevention, NCI

8:30-9:30 AM Translational Research Plenary Speaker

Raymond DuBois, M.D., Ph.D., Medical University of South Carolina

Inflammation and inflammatory mediators as targets for cancer prevention/interception



Session I*

Advances in Small Molecule Agent Development

Co-Chairs: Margie Clapper, Ph.D. and Thomas Kensler, Ph.D.

9:30-10:00 AM Speaker 1: Margie Clapper, Ph.D. Fox Chase Cancer Center

Estrogen metabolism: A target for intervention in non-small cell lung cancer


10:00-10:30 AM Speaker 2: Thomas Kensler, Ph.D., Fred Hutchinson Cancer Research Center

Bringing broccoli sprouts (Sulforaphane) to clinical trials: dose matters

10:30-10:50 AM Break

10:50-11:20 AM Speaker 3: Zelton (Dave) Sharp, Ph.D., University of Texas at San Antonio

Cancer and aging prevention by mTOR inhibition

11:20-11:50 AM Speaker 4: Karen Liby, Ph.D., Michigan State University

Targeting the immune system for the prevention of Kras-driven cancers

11:50-1:15 PM Lunch

Day 1 Afternoon Session (1:15 to 4:30)

Session II

Advances in Immunomodulatory Agent Development

Co-chairs: Jill Siegfried, Ph.D. and Robert H. Shoemaker, Ph.D.

1:15-1:45 PM Speaker 1: Jill Siegfried, Ph.D., University of Minnesota

A STAT3 decoy for lung cancer prevention

1:45-2:15 PM Speaker 2: Robert Glynn, Sc.D., Harvard Medical School

Mediation analysis to elucidate the role of inflammation reduction in cancer prevention: exploratory findings from the CANTOS trial

2:15-2:45 PM Speaker 3: Haval Shirwan, Ph.D., University of Missouri, Columbia

CD137 immune checkpoint pathway as an effective target for cancer immunoprevention

2:45-3:00 PM Break

3:00-3:30 PM Speaker 4: Shadmehr Demehri, M.D., Ph.D., Massachusetts General Hospital

Epithelium-derived alarmins role in breast cancer immunoprevention

3:30-3:50 PM NCI PREVENT Preclinical Drug Development Program

Mark Miller, Ph.D., Division of Cancer Prevention, NCI

Q&A Session until 4:30 PM



4:30-6:00 PM Poster Session







Day 2 Morning Session (9:00 to12:00)

Session III

Alternative Dosing and Combination Strategies to Reduce Toxicity

Co-Chairs: Ming You, M.D., Ph.D. and Altaf Mohammed, Ph.D.

9:00-9:30 AM Speaker 1: Ming You, M.D., Ph.D., Wisconsin Medical Center

Chemoprevention with aerosolized let-7 micro-RNA in mouse models of lung cancer

9:30-10:00 AM Speaker 2: Susan Mallery, D.D.S., Ph.D., Ohio State University

Location, location, location: oral cancer chemoprevention by local delivery

10:00-10:30 AM Speaker 3: C.V. Rao, Ph.D., University of Oklahoma

Safer chemopreventive approaches to colonic adenoma prevention

10:30-10:45 AM Break

10:45-11:15 AM Speaker 4: D. Lynn Kirkpatrick, Ph.D., PHusis Therapeutics

Preventing Skin cancer in high risk individuals with Actinic Keratosis using targeted AKT/PDK1 inhibitor, PHT-427

11:15-11:45 AM Speaker 5: Roderick Dashwood, Ph.D., Texas A&M Health Science Center

Optimizing dosing regimens of Erlotinib and Sulindac in a preclinical model of FAP

11:45-1:00 PM Lunch







Day 2 Afternoon Session (1:00 to 4:00)

Session IV

Emerging Vaccines for Cancer Prevention

Co-Chairs: Steven Lipkin, M.D., Ph.D. and Shizuko Sei, M.D.

1:00-1:30 PM Speaker 1: Steven Lipkin, M.D., Ph.D. Weill Cornell University

Immunoprevention for Lynch Syndrome

1:30-2:00 PM Speaker 2: Mary (Nora) Disis, M.D., University of Washington

Vaccines targeting cancer initiation associated proteins

2:00-2:30 PM Speaker 3: Richard Roden, Ph.D., Johns Hopkins University

Development of vaccines for broad protection against and elimination of HPV infection

2:30-2:50 PM Break

2:50-3:20 PM Speaker 4: Robert Schoen, M.D., M.P.H., University of Pittsburgh

MUC1 vaccine for prevention of colorectal adenoma

3:20-3:50 PM Speaker 5: Bryon Johnson, Ph.D., Wisconsin Medical Center

Development of a Kras preventive vaccine



4:00-6:00 PM Poster Session







Day 3 Morning Session (8:00 to 12:00)

8:00-9:00 AM Clinical Research Plenary Speaker

Powel Brown, M.D., Ph.D., MD Anderson Cancer Center

Novel cancer prevention strategies in the molecular era

Session V

Cancer Prevention Clinical Trials

Co-Chairs: Peter Allen and Eva Szabo

9:00-9:15 AM Overview of the Cancer Prevention Clinical Trials Network (CP-CTNet)

Eva Szabo, M.D., Division of Cancer Prevention, NCI

Q&A to 9:30 AM



9:30-10:00 AM Speaker 1: Peter Allen, M.D., Duke University

Intraductal Papillary Mucinous neoplasms of the pancreas:  An opportunity to prevent pancreatic cancer?

10:00-10:30 AM Speaker 2, Eduardo Vilar-Sanchez, M.D., Ph.D., MD Anderson Cancer Center

Cancer immune-interception for Lynch Syndrome

10:30-10:50 AM Break

10:50-11:20 AM Speaker 3: Seema Khan, M.D., Northwestern University

Local transdermal drug delivery to the breast for cancer prevention

11:20-11:50 AM Speaker 4: Andrew Chan, M.D., M.P.H., Massachusetts General Hospital

Novel strategies for aspirin prevention of cancer

12:00 PM Adjourn

File Typeapplication/vnd.openxmlformats-officedocument.wordprocessingml.document
File TitleFast Track’s
SubjectWith Examples
AuthorNCI PRA OMB Team
File Modified0000-00-00
File Created2022-02-01

© 2024 OMB.report | Privacy Policy